Skip to content

Addiction: all studies

Page 99 of 855: studies 981 to 990 of 8,547, newest first. Back to the addiction overview

Research

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Journal of Psychoactive Drugs May 8, 2017 Kelan Thomas, Benjamin Malcolm, Dan Lastra 77 citations

Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psychopathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have...

Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective

Neurotherapeutics May 5, 2017 Ben Sessa 11 citations

Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug's medical potential. MDMA has unique...

New psychoactive substances of natural origin: A brief review

Journal of Food and Drug Analysis April 18, 2017 Ling‐yi Feng, Altansuvd Battulga, Eunyoung Han et al. 86 citations

Plant-based drugs of abuse are as old as recorded human history. Although traditional addictive substances, such as opium, cannabis and coca, have been controlled by the United Nations anti-drug conventions, many, if not most, natural plants with addictive or abuse liability remain elusive. Therefore, the United Nations Office on Drugs and Crime (UNODC) has warned the emerging threat from new...

The antiaddictive effects of ibogaine: A systematic literature review of human studies

Journal of Psychedelic Studies April 1, 2017 Rafael G. Dos Santos, José Carlos Bouso, Jaime E. C. Hallak 36 citations

Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Papers published up to July 2, 2016 were included...

DOI: 10.1556/2054.01.2016.001 (opens in new tab) Addiction Opiate Hallucinogen Pharmacology +5

Aleister Crowley on Drugs

International Journal for the Study of New Religions February 20, 2017 Christopher Partridge 1 citation

While much has been written about the life, work and influence of Aleister Crowley, relatively little attention has been directed to his drug use. This is a little surprising because, not only did he become addicted to heroin, but he incorporated psychoactive substances in his occult work, discussed their psychological effects, commented on drug-related social issues, critiqued contemporary...

How much alcohol is in ketamine's antidepressant action?

Life Sciences January 1, 2017 Udo Bonnet

Ketamine is approved to start and maintain anaesthesia or analgesia. Ketamine is also known to be neurotoxic and an old drug of abuse. Numerous studies have proven a rapid and strong antidepressant response (AR) following parenteral sub-anaesthetic ketamine doses when applied the first time to patients with treatment resistant unipolar or bipolar major depression. This rapid and robust AR is...

Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration.

Current Topics in Behavioral Neurosciences 2017 Shawn. M. Aarde, Michael A. Taffe

Animal models of drug self-administration are currently the gold standard for making predictions regarding the relative likelihood that a recreational drug substance will lead to continued use and addiction. Such models have been found to have high predictive accuracy and discriminative validity for a number of drug classes including ethanol, nicotine, opioids, and psychostimulants such as...

Salience attribution and its relationship to cannabis-induced psychotic symptoms.

Psychological Medicine December 2016 Michael Bloomfield, E Mouchlianitis, C J A Morgan et al.

Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. We tested 17 cannabis users and 17 age- and...

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.

Journal of Psychopharmacology November 15, 2016 Clinton E. Canal, Kevin S. Murnane

Classic hallucinogens share pharmacology as serotonin 5-HT 2A , 5-HT 2B , and 5-HT 2C receptor agonists. Unique among most other Schedule 1 drugs, they are generally non-addictive and can be effective tools in the treatment of addiction. Mechanisms underlying these attributes are largely unknown. However, many preclinical studies show that 5-HT 2C agonists counteract the addictive effects of...

Psychedelics as Medicines: An Emerging New Paradigm

Clinical Pharmacology & Therapeutics November 4, 2016 De Nichols, Mw Johnson, Cd Nichols 366 citations

Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT 2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that...